Clinical trials have validated the efficacy of trastuzumab in significantly lowering mortality and recurrence rates while enhancing survival, leading to its recommendation for both early-stage and metastatic HER-2 positive breast cancers [4–7]. The gene discussed is ERBB2; the disease is breast carcinoma.